Sciele Pharma Inc: Premium Company Profile

Introduction

The company was founded in 1992 as First Horizon Pharmaceutical and later in 2006, changed its name to Sciele Pharma. The company’s therapeutic focus is on cardiovascular/metabolic and women's health.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Sciele Pharma engages in sales, marketing and development of branded prescription products. The company currently markets and sells 16 products, 10 of which are actively promoted. The company markets products related to indications cardiovascular, diabetes and women’s health. Sciele Pharma’s cardiovascular / diabetes related products include Altoprev, Fortamet, Nitrolingual, Triglide and sular and women’s health related products include Optinate, Ostiva, Ponstel, Prenate Elite and Zovirax. The company’s total revenues increased at a CAGR of 26% during 2002-2006, from $115 million to $293 million. The company’s biggest contributor to revenue growth during 2002-2006 was sales of cardiovascular / diabetes related products - Altoprev, Fortamet, Nitrolingual, Triglide and sular.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .

Report Highlights

[Studien Infos ausblenden]